Price to FCFE (P/FCFE)

Free Cash Flow to Equity (FCFE)
P to FCFE Ratio, Current
P to FCFE Ratio, Historical

Paying user area

Try for free

Pfizer Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get full access to the entire website from $10.42/mo, or
get 1-month access to Pfizer Inc. for $24.99.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Free Cash Flow to Equity (FCFE)

Pfizer Inc., FCFE calculation

US$ in millions

	12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
	Net income attributable to Pfizer Inc. common shareholders
	Net income attributable to noncontrolling interests
	Net noncash charges
	Other changes in assets and liabilities, net of acquisitions and divestitures
	Net cash provided by operating activities
	Purchases of property, plant and equipment
	Proceeds from short-term borrowings
	Payments on short-term borrowings
	Net proceeds from (payments on) short-term borrowings with original maturities of three months or less
	Proceeds from issuances of long-term debt
	Payments on long-term debt
	Free cash flow to equity (FCFE)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Item	Description	The company
FCFE	Free cash flow to equity is the cash flow available to Pfizer Inc. equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made.	Pfizer Inc. FCFE increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.

Price to FCFE Ratio, Current

Pfizer Inc., current P/FCFE calculation, comparison to benchmarks

No. shares of common stock outstanding
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in millions)
FCFE per share
Current share price (P)
Valuation Ratio
P/FCFE
Benchmarks
P/FCFE, Competitors¹
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
P/FCFE, Sector
Pharmaceuticals, Biotechnology & Life Sciences
P/FCFE, Industry
Health Care

Based on: 10-K (reporting date: 2024-12-31).

¹ Click competitor name to see calculations.

If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.

Price to FCFE Ratio, Historical

Pfizer Inc., historical P/FCFE calculation, comparison to benchmarks

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
	No. shares of common stock outstanding¹
	Selected Financial Data (US$)
	Free cash flow to equity (FCFE) (in millions)²
	FCFE per share³
	Share price^1, 4
	Valuation Ratio
	P/FCFE⁵
	Benchmarks
	P/FCFE, Competitors⁶
	AbbVie Inc.
	Amgen Inc.
	Bristol-Myers Squibb Co.
	Danaher Corp.
	Eli Lilly & Co.
	Gilead Sciences Inc.
	Johnson & Johnson
	Merck & Co. Inc.
	Regeneron Pharmaceuticals Inc.
	Thermo Fisher Scientific Inc.
	Vertex Pharmaceuticals Inc.
	P/FCFE, Sector
	Pharmaceuticals, Biotechnology & Life Sciences
	P/FCFE, Industry
	Health Care

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

¹ Data adjusted for splits and stock dividends.

² See details »

³ 2024 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= ÷ =

⁴ Closing price as at the filing date of Pfizer Inc. Annual Report.

⁵ 2024 Calculation
P/FCFE = Share price ÷ FCFE per share
= ÷ =

⁶ Click competitor name to see calculations.